XNAS
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
Biotech IPO stumbles with massive **$3.10 EPS miss** at $-3.65, suggesting higher-than-expected R&D burn rates. Early-stage therapeutic development costs likely exceeding projections.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | Q1 2026 | -0.55 | -3.65 | -563.64% | $0 | ❌ Miss | +0.14% | +4.73% | — |
Showing last 1 quarters.